Verastem (VSTM)
(Delayed Data from NSDQ)
$2.88 USD
+0.05 (1.77%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $2.88 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 181 - 200 ( 267 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Wait For NSCLC PhII Data at WCLC; Sell-Off Ignores Main Value Driver
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
COMMAND''s First Hurdle Coming Up; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Results; Let''s See Where COMMAND Interim Leads Us
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage of Three Unique Plays in Oncology
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
On the Road to Curing Cancer: Recent Developments and Future Outlook
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Update-COMMAND Interim Analysis Pushed Back; CSCs a Hot Topic at AACR
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Results; Busy 2H15 with Interim Analysis and Data Updates
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2015 AACR Meeting Highlights-Cancer Gets a Dose of Brotherly Love
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Targeting the Achilles? Heel of Cancer-the Elusive Cancer Stem Cell; Initiating with Buy Rating
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2014 Results; COMMAND Interim and Maybe Some NSCLC Surprises Coming
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Coffers Topped Off; Driving COMMAND Forward; Tweaking Target to $23
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
''6063 - ''5584 Combo Study Initiated; Anticipating COMMAND Interim Outcome
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Data Rich 2015 Ahead with Main Focus on COMMAND; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Results; Clinical Programs Moving Full Steam Ahead; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J